68 results
Page 3 of 4
8-K
EX-3.1
3dny1itw 0x809
5 Jul 18
Material Modifications to Rights of Security Holders
4:03pm
S-1MEF
EX-5.1
s93uuqznoj
22 Jun 18
Registration of additional securities for an S-1
4:05pm
S-1MEF
EX-8.1
8vmb7xmf93dz9mafkq2
22 Jun 18
Registration of additional securities for an S-1
4:05pm
424B4
fqiy7ir4
15 Jun 18
Prospectus supplement with pricing info
12:26pm
FWP
orqy8 wkxjr1dqvr
5 Jun 18
Free writing prospectus
4:31pm
10-KT
lrqj y7jburq
26 Mar 18
Annual report (with FYE transition)
12:00am
424B5
mni 3yhgpp01n09oe
7 Oct 15
Prospectus supplement for primary offering
12:00am
8-K
EX-1.1
ghi2vjor3qhgng
7 Oct 15
Contravir Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
12:00am
8-K
EX-10.1
abiqz
15 Oct 14
ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
12:00am
10-K
84m6b1ox
29 Sep 14
Annual report
12:00am
8-K
EX-10.1
7bxd6bx501a0is2784a
20 Mar 14
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
12:00am
10-12G/A
EX-99.1
01muiutmbc5ltqgu
6 Feb 14
Registration of securities (amended)
12:00am
8-K
EX-10.1
px9ker6f9p7k
5 Feb 14
Entry into a Material Definitive Agreement
12:00am
10-12G/A
EX-99.1
q3ao4a1e
24 Dec 13
Registration of securities (amended)
12:00am